EDSA
Edesa Biotech Inc
3.90$
+1.3%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -85.7% | -375.3% | -1,380.1% | -536.2% | -1,146.6% | -581.6% | -354.3% | -2,058.7% | -2,178.7% | -1,179.4% | -1,516.5% | -2,732,986.2% | – | – | – | – | |
| – | 1.6% | 12.5% | 39.2% | 22.9% | 42.5% | 21.0% | 11.8% | 78.6% | 88.9% | 1.2% | 17.5% | 23,757.6% | – | – | – | – | |
| – | 39.8% | 574.8% | 670.0% | 115.0% | 257.1% | 35.2% | 20.4% | 50.6% | 72.8% | 11.3% | 182.0% | 639,093.8% | – | – | – | – | |
| – | – | – | – | – | – | – | – | 65.5% | 38.4% | 11.3% | 182.0% | 639,093.8% | – | – | – | – | |
| – | -13.2% | 54.3% | 153.7% | -78.7% | 55.9% | -68.3% | -1.9% | 86.8% | 6.2% | -513.3% | 219.6% | -727,207.6% | – | – | – | – | |
| – | 10.4% | 44.4% | 27.4% | 1.7% | 75.0% | 36.2% | 31.6% | 132.6% | 180.7% | 2.0% | 10.4% | 1,229.2% | – | – | – | – | |
| – | -10.4% | -44.4% | -27.4% | -1.7% | -199.2% | 16.1% | 43.8% | 741.0% | -2,108.3% | 1,562.0% | 5.8% | -1,229.2% | – | – | – | – | |
| – | – | -17.9% | – | – | – | 14.1% | 601.2% | – | 4,329.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | 194.0% | 14.0% | 7.2% | 9.0% | 0.0% | – | – | – | – | |
| – | 329.4% | 727.0% | 306.7% | 1,783.9% | 2,899.0% | 14.1% | 575.1% | 2.6% | 4,140.8% | 1,726.3% | 2,157.2% | 2,834,948.0% | – | – | – | – | |
| – | 233.4% | 307.3% | -1,100.0% | 1,257.8% | 1,496.1% | -634.4% | 272.2% | -1,246.7% | -163.1% | 404.9% | 664.0% | 125,112.8% | – | – | – | – | |
| – | -96.1% | -419.7% | -1,407.5% | -538.0% | -1,221.5% | -617.8% | -385.9% | -2,191.3% | -2,359.4% | -1,181.4% | -1,527.0% | -2,734,215.4% | – | – | – | – |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.